GlassScriptPhysician profile
Jose Escandon
NPI 1316184302
$11,116.93
in general payments reported to CMS, 2019-2025
31 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,189 · 2020: $2,655 · 2021: $1,126 · 2022: $1,427 · 2023: $1,419 · 2024: $776 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,124.48 | 2019-2021 | |
| Novo Nordisk INC | $2,249.42 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,906.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $557.54 | 2019-2023 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $437.32 | 2019-2025 | |
| Abbvie INC. | $400.71 | 2019-2025 | |
| Lilly USA, LLC | $298.51 | 2019-2023 | Mounjaro, Trulicity, Zepbound |
| Ironwood Pharmaceuticals, INC | $281.38 | 2019-2024 | Linzess |
| Amarin Pharma, INC. | $250.28 | 2019-2021 | |
| Dexcom, INC. | $249.62 | 2022-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $203.43 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Allergan, INC. | $146.82 | 2019-2022 | |
| Astellas Pharma US INC | $145.11 | 2019-2022 | |
| Exact Sciences Corporation | $134.63 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.65 | 2019-2024 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $109.97 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $83.22 | 2021-2023 | |
| Optinose US, INC. | $66.87 | 2022-2024 | |
| Abbott Laboratories | $48.07 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.50 | 2020-2022 | |
| Averitas Pharma INC. | $37.75 | 2024 | Qutenza |
| Corcept Therapeutics | $33.40 | 2024 | Korlym |
| Radius Health, INC. | $21.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.98 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $19.78 | 2024 | Gemtesa |
| Biogen, INC. | $17.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Evoke Pharma, INC. | $12.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Escandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.